- IN8bio Inc IN FROM new dates announced from the investigator-sponsored Phase 1 study of INB-100 in leukemia patients.
- The data showed that 100% of evaluable patients (n=7) treated with INB-100 survived, were progression free and in durable complete response (CR) as of April 21, 2023.
- The latest data showed significant allogeneic expansion and persistence of allogeneic gamma delta T cells in patients during the first 180 days after treatment.
- Patients receiving INB-100 dose level 2 treatment demonstrated a mean 82.9-fold greater gamma-delta T-cell expansion at 60 days compared to patients undergoing haploidentical HSCT without INB-100 treatment. undergone therapy.
- Gamma-delta T cell levels in patients at dose level 2 are also on average 12.8-fold higher than those achieved at dose level 1, demonstrating a dose-response relationship with gamma-delta T cell infusion. Increases in CD4+, CD8+ T cells, NK cells and B cells were also observed, indicating a broad positive immune response.
- The updated study safety data reported low grade (1-2) graft-versus-host disease (GvHD) in all treated patients, which was steroid-responsive and had a faster onset with higher doses.
- No dose-limiting toxicities were observed.
- Price promotion: INAB shares are up 140% at $2.52 as of Monday’s latest check.
© 2023 Benzinga.de. Benzinga does not provide investment advice. All rights reserved.
[ad_2]
Source story
